IGM Biosciences
Yahoo Finance • last year
15 Best Falling Stocks To Buy Now
In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falli... Full story
Yahoo Finance • last year
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The general meeting was held at Helio GT3... Full story
Yahoo Finance • last year
IGM Biosciences Announces Third Quarter 2023 Financial Results
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinica... Full story
Yahoo Finance • last year
Robert Bruce's Investment Strategy Leads to Notable Changes in Portfolio, Highlighting Merck ...
Insight into the Latest 13F Filing Reveals Key Stock Adjustments by Value Investing Firm Bruce & Co Renowned for his value investing approach, Robert Bruce (Trades, Portfolio), the founder of Bruce & Co., has recently disclosed his firm's... Full story
Yahoo Finance • last year
IGM Biosciences to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chie... Full story
Yahoo Finance • last year
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D... Full story
Yahoo Finance • last year
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Ch... Full story
Yahoo Finance • last year
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its voting common stock and... Full story
Yahoo Finance • 2 years ago
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of... Full story
Yahoo Finance • 2 years ago
IGM Announces Proposed Public Offering and Concurrent Private Placement
MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to... Full story
Yahoo Finance • 2 years ago
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without... Full story
Yahoo Finance • 2 years ago
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chi... Full story
Yahoo Finance • 2 years ago
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023
MOUNTAIN VIEW, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of six... Full story
Yahoo Finance • 2 years ago
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its... Full story
Yahoo Finance • 2 years ago
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chie... Full story
Yahoo Finance • 2 years ago
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
MOUNTAIN VIEW, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient ha... Full story
Yahoo Finance • 2 years ago
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive... Full story
Yahoo Finance • 2 years ago
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM’s... Full story
Yahoo Finance • 2 years ago
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive... Full story
Yahoo Finance • 2 years ago
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive... Full story
